Distinguished in Ovarian Carcinosarcoma

Dr. Alberto Mendivil

Oncology
Providence
16105 Sand Canyon Avenue, Suite 260, 
Irvine, CA 
Accepting New Patients
Distinguished in Ovarian Carcinosarcoma
Providence
16105 Sand Canyon Avenue, Suite 260, 
Irvine, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alberto Mendivil is an Oncologist in Irvine, California. Dr. Mendivil is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Hernia Surgery. Dr. Mendivil is currently accepting new patients.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Obstetrics & Gynecology in CA
Hospital Affiliations
Providence St. Joseph Hospital
Hoag Memorial Hospital Presbyterian
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

16105 Sand Canyon Avenue, Suite 260, Irvine, CA 92618
Call: 949-642-1361

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Afuresertib
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Enrollment Status: Completed
Publish Date: January 05, 2023
Intervention Type: Biological
Study Drugs: GL-ONC1, Chemotherapy, Bevacizumab
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Enrollment Status: Unknown
Publish Date: April 25, 2022
Intervention Type: Biological
Study Drugs: AVOVA-1, MC
Study Phase: Phase 2
View 11 Less Clinical Trials

37 Total Publications

Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191].
Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191].
Journal: Gynecologic oncology
Published: November 07, 2025
View All 37 Publications
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. John V. Brown
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. John V. Brown
Oncology
16105 Sand Canyon Avenue, Suite 260, 
Irvine, CA 
 (0.1 miles away)
949-642-1361
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Brown is an Oncologist in Irvine, California. Dr. Brown is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Sertoli-Leydig Cell Tumor, and Malignant Mixed Mullerian Tumor. Dr. Brown is currently accepting new patients.

Distinguished in Ovarian Carcinosarcoma
Dr. Joshua G. Cohen
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Joshua G. Cohen
Oncology
2151 North Harbor Boulevard, Suite 3100, 
Anchorage, CA 
 (19.4 miles away)
714-446-5830
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Cohen is an Oncologist in Anchorage, California. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Lymphadenectomy. Dr. Cohen is currently accepting new patients.

Distinguished in Ovarian Carcinosarcoma
Dr. Krishnansu S. Tewari
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Krishnansu S. Tewari
Oncology
1000 West La Veta Avenue, Floor 1, 
Orange, CA 
 (10.9 miles away)
714-734-6225
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Krishnansu Tewari is an Oncologist in Orange, California. Dr. Tewari is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Lymphadenectomy. Dr. Tewari is currently accepting new patients.

VIEW MORE OVARIAN CARCINOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mendivil's expertise for a condition
ConditionClose
    • Distinguished
    • Endometrial Cancer
      Dr. Mendivil is
      Distinguished
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Malignant Mixed Mullerian Tumor
      Dr. Mendivil is
      Distinguished
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Ovarian Cancer
      Dr. Mendivil is
      Distinguished
      . Learn about Ovarian Cancer.
      See more Ovarian Cancer experts
    • Ovarian Carcinosarcoma
      Dr. Mendivil is
      Distinguished
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Sertoli-Leydig Cell Tumor
      Dr. Mendivil is
      Distinguished
      . Learn about Sertoli-Leydig Cell Tumor.
      See more Sertoli-Leydig Cell Tumor experts
    • Testicular Yolk Sac Tumor
      Dr. Mendivil is
      Distinguished
      . Learn about Testicular Yolk Sac Tumor.
      See more Testicular Yolk Sac Tumor experts
    View All 7 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Mendivil is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Angiomyoma
      Dr. Mendivil is
      Advanced
      . Learn about Angiomyoma.
      See more Angiomyoma experts
    • Cervical Cancer
      Dr. Mendivil is
      Advanced
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Mendivil is
      Advanced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Pseudomyxoma Peritonei
      Dr. Mendivil is
      Advanced
      . Learn about Pseudomyxoma Peritonei.
      See more Pseudomyxoma Peritonei experts
    • Vulvar Cancer
      Dr. Mendivil is
      Advanced
      . Learn about Vulvar Cancer.
      See more Vulvar Cancer experts
    • Experienced
    • Agranulocytosis
      Dr. Mendivil is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • DICER1 Syndrome
      Dr. Mendivil is
      Experienced
      . Learn about DICER1 Syndrome.
      See more DICER1 Syndrome experts
    • Endoscopy
      Dr. Mendivil is
      Experienced
      . Learn about Endoscopy.
      See more Endoscopy experts
    • Hemangiopericytoma
      Dr. Mendivil is
      Experienced
      . Learn about Hemangiopericytoma.
      See more Hemangiopericytoma experts
    • Hernia Surgery
      Dr. Mendivil is
      Experienced
      . Learn about Hernia Surgery.
      See more Hernia Surgery experts
    • Melanoma
      Dr. Mendivil is
      Experienced
      . Learn about Melanoma.
      See more Melanoma experts
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.